Inspyr Therapeutics, Inc. Announces Executive Appointments
March 06, 2017 at 09:00 am
Share
Inspyr Therapeutics, Inc. announced the appointments of David Maloney, and Matthew Boxer, as Vice Presidents and Co-heads of Translational Medicine. They join the company from the National Institutes of Health (NIH) to lead Inspyr's translational medicine function, focused on designing, implementing, and managing all aspects of lead asset Mipsagargin's preclinical studies, including new combination studies, as well as new asset development. Matthew Boxer most recently at NCATS, where he was Medicinal Chemistry Group Leader. David Maloney, Ph.D. joined Inspyr following a nine-year career at the NIH’s National Center for Advancing Translational Sciences (NCATS), where he was a Group Leader in Chemistry and co-led an interdisciplinary project team. Most recently, he co-led a multi-center, NCI-funded drug discovery effort targeting an enzyme involved in cancer metabolism. Matthew Boxer, Ph.D. joined Inspyr following a nine-year career at the NIH, most recently at NCATS, where he was Medicinal Chemistry Group Leader. Recently, Matthew was project lead on a multi-institutional drug discovery project targeting an enzyme frequently mutated in cancer, and delivered a compound ready for investigational new drug (IND)-enabling studies.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.